Saturday 17 October 2026
Export ALGS’s income statement to Excel — free account
Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 2,778.6%, EPS grew 90.9% and free cash flow fell 59.8%, each against the same quarter a year earlier.
4.86
0.53
−9.83%
Follow ALGS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.91 | 16.43 | 42.14 | 38.41 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.41) | (3.34) | (4.24) | (4.17) | |
P/B ratio |
1.89 | 2.43 | 1.72 | 1.41 | |
Price to Tangible BV |
1.89 | 2.43 | 1.72 | 1.41 | |
EV/Sales |
0.95 | 4.75 | 6.54 | 0.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.32) | (0.26) | (0.17) | (0.03) | |
EV/FCF |
(0.32) | (0.26) | (0.17) | (0.03) | |
Quick Ratio |
2.05 | 2.36 | 3.67 | 4.51 | |
Current Ratio |
2.19 | 2.56 | 3.90 | 4.70 | |
Net Debt/EBITDA |
17.82 | 2.04 | 3.33 | 3.61 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.11% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.04 | 0.03 | 0.03 | |
Operating CF/Net income |
16.59 | 1.00 | 1.09 | 0.77 | |
Capex/Depreciation |
(0.01) | 0.95 | 0.06 | (0.22) | |
Research and Development Expense of Revenue |
86.58% | 825.16% | 10,081.66% | 3,230.36% | |
Selling, General and Administrative Expense of Revenue |
20.22% | 226.40% | 2,926.04% | 697.03% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
4.91% | 46.43% | 862.72% | 197.98% | |
Graham Net Nets |
0.46 | 0.35 | 0.52 | 0.64 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(126.52%) | (116.96%) | (14.59%) | (127.86%) | |
Free Cash Flow Yield |
(157.05%) | (110.21%) | (90.03%) | (78.27%) | |
Revenue per Share |
2.66 | 0.27 | 0.02 | 0.07 | |
Operating CF per Share |
(2.39) | (2.22) | (2.20) | (2.35) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(2.39) | (2.23) | (2.21) | (2.37) | |
Cash per Share |
2.92 | 5.29 | 7.89 | 9.57 | |
Shareholders Equity per Share |
3.06 | 3.06 | 5.42 | 6.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.06 | 3.06 | 5.42 | 6.93 | |
Free Cash Flow |
(24.95) | (23.20) | (21.84) | (24.54) | |
Working Capital |
33.78 | 36.31 | 61.63 | 81.45 | |
Capital Expenditures |
0.00 | (0.07) | (0.09) | (0.19) | |
Net Current Asset Value |
27.68 | 26.86 | 47.87 | 65.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.54 | 0.26 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.18 | 6.05 | 3.28 | 3.70 | |
Average Assets |
100.52 | 107.63 | 79.31 | 99.10 | |
Average Common Equity |
66.87 | 74.12 | 12.29 | 60.96 |
Columns are period end dates